Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 624-630

  Salgia, Ravi ^a   Lynch, Thomas ^a   Skarin, Arthur ^a   Lucca, Joan ^a   Lynch, Cathleen ^a   Jung, Ken ^a   Hodi, F Stephen ^a   Jaklitsch, Michael ^a   Mentzer, Steve ^a   Swanson, Scott ^a   Lukanich, Jean ^a   Bueno, Raphael ^a   Wain, John ^a   Mathisen, Douglas ^a   Wright, Cameron ^a   Fidias, Panos ^a   Donahue, Dean ^a   Clift, Shirley ^a   Hardy, Steve ^a   Neuberg, Donna ^a   Mulligan, Richard ^a   Webb, Iain ^a   Sugarbaker, David ^a   Mihm, Martin ^a   Dranoff, Glenn ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; CANCER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL SUSPENSION; CLINICAL ARTICLE; CRYOPRESERVATION; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DISEASE DURATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; ADULT; AGED; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY;

ADULT; AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0037441842     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.091     Document Type: Article

References (37)

1. Brass N, Heckel D, Sahin U, et al: Translation initiation factor eIF-4 gamma is encoded by an amplified gene and induces an immune response in squamous cell carcinoma. Hum Mol Genet 6:33-39, 1997
2. Cure A, Altorki N, Stocken E, et al: Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 58:1034-1041, 1998
3. Brass N, Racz A, Bauer C, et al: Role of amplified genes in the production of antibodies. Blood 93:2158-2166, 1999
4. Gure A, Stockert E, Scanlan M, et al: Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97:4198-4203, 2000
5. Winter S, Sekido Y, Minna J, et al: Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival. J Natl Cancer Inst 85:2012-2018, 1993
6. Yoshino I, Goedegebuure PS, Peoples GE, et al: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387-3390, 1994
7. Hogan K, Eisinger D, Cupp S, et al: The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 58:5144-5150, 1998
8. Shichijo S, Nakao M, Imai Y, et al: A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277-288, 1998
9. Gomi S, Nakao M, Niiya F, et al: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 163:4994-5004, 1999
10. Yang D, Nakao M, Shichijo S, et al: Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59:4056-4063, 1999
11. Nakao M, Shichijo S, Imaizumi T, et al: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164:2565-2574, 2000
12. Kawano K, Gomi S, Tanaka K, et al: Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 60:3550-3558, 2000
13. Nishizaka S, Gomi S, Harada K, et al: A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 60:4830-4837, 2000
14. Echchakir H, Mami-Chouaib F, Vergnon I, et al: A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 61:4078-4083, 2001
15. Karanikas V, Colau D, Baurain JF, et al: High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61:3718-3724, 2001
16. Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12:571-575, 2000
17. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993
18. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965, 1994
19. Mach N, Gillessen S, Wilson SB, et al: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res 60:3239-3246, 2000
20. Reilly R, Machiels J-P, Emens L, et al: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880-883, 2001
21. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95:13141-13146, 1998
22. Shenk T: Adenoviridae: The viruses and their replication, in Fields BN, Knipe DM, Howley PM (eds): Fields Virology (ed 3). Philadelphia, PA, Lippincott-Raven, 1996, pp 2111-2148
23. Hardy S, Kitamura M, Harris-Stansil T, et al: Construction of adenovirus vectors through cre-lox recombination. J Virol 71:1842-1849, 1997
24. Cullen BR: Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973-982, 1986
25. Dranoff G, Soiffer R, Lynch T, et al: A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 8:111-123, 1997
26. Murphy G, Bhan A, Sato S, et al: A new immunologic marker for human Langerhan cells. N Engl J Med 304:791-792, 1981
27. Old L, Chen Y-T: New paths in human cancer serology. J Exp Med 187:1163-1167, 1998
28. Kochanek S, Clemens PR, Mitani K, et al: A new adenoviral vector-replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 93:5731-5736, 1996
29. Perlin E, Oldham R, Weese J, et al: Carcinoma of the lung: Immunotherapy with intradermal BCG and allogeneic tumor cells. Int J Radiat Oncol Biol Phys 6:1033-1039, 1980
30. Schulof R, Mai D, Nelson M, et al: Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother 1:30-36, 1988
31. Hodi FS, Schmollinger JC, Soiffer RJ, et al: ATP6S1 elicits potent humoral responses associated with immune mediated tumor destruction. Proc Natl Acad Sci U S A 99:6919-6924, 2002
32. Jäger E, Nagata Y, Gnjatic S, et al: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 97:4760-4765, 2000
33. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A 98:3964-3969, 2001
34. Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546, 1997
35. Simons J, Mikhak B, Chang J-F, et al: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160-5168, 1999
36. Jaffee E, Hruban R, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19:145-156, 2001
37. van Elsas A, Hurwitz A, Allison J: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999